These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36929411)

  • 21. Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion.
    Shefer HK; Masarwe I; Bejar J; Naamnih LH; Gueta-Milshtein K; Shalata A; Hadid Y; Nativ O; Nativ O
    Urol Oncol; 2023 Jun; 41(6):296.e1-296.e8. PubMed ID: 36642638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis.
    Chen GL; El-Gabry EA; Bagley DH
    J Urol; 2000 Dec; 164(6):1901-4. PubMed ID: 11061876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
    Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
    Ragonese M; Gianfrancesco LD; Palermo G; Pierconti F; Martini M; Foti M; Bassi P; Racioppi M
    Clin Genitourin Cancer; 2022 Aug; 20(4):e271-e275. PubMed ID: 35871875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
    Haas M; Kriegmair MC; Breyer J; Sikic D; Wezel F; Roghmann F; Brehmer M; Wirtz RM; Jarczyk J; Erben P; Bahlinger V; Goldschmidt F; Fechner G; Chen J; Paxinos E; Bates M; Zengerling F; Bolenz C; Burger M; Hartmann A; Eckstein M
    BJU Int; 2024 May; ():. PubMed ID: 38717014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer.
    Fernández MI; Parikh S; Grossman HB; Katz R; Matin SF; Dinney CP; Kamat AM
    Urol Oncol; 2012; 30(6):821-4. PubMed ID: 21396845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma.
    Mian C; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Lusuardi L; Palermo S; Marberger M; Pycha A
    Cytopathology; 2003 Dec; 14(6):338-42. PubMed ID: 14632732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder.
    Fritsche HM; Burger M; Dietmaier W; Denzinger S; Bach E; Otto W; Doblinger M; Schwarz S; Buchner H; Hartmann A
    Am J Clin Pathol; 2010 Oct; 134(4):597-603. PubMed ID: 20855641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation study of the Paris system for reporting urinary (TPS) categories.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
    J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Urinary cytology. Possibilities, limitations and the future].
    Zaak D; Tritschler S; Knuechel R; Vom Dorp F; Hakenberg OW; Hautmann S; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():97-101. PubMed ID: 16821054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients.
    Nagai T; Okamura T; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Yasui T
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1271-1273. PubMed ID: 31030505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study.
    Freund JE; Liem EIML; Savci-Heijink CD; de Reijke TM
    Med Oncol; 2018 Nov; 36(1):10. PubMed ID: 30499061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis.
    Sano T; Yoshida T; Nakamoto T; Ohe C; Taniguchi H; Yanishi M; Kinoshita H
    World J Urol; 2024 Jul; 42(1):389. PubMed ID: 38985343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of Xpert
    D'Elia C; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Spedicato GA; Pycha S; Vjaters E; Degener S; Kafka M; Pycha A; Trenti E
    Ther Adv Urol; 2021; 13():1756287221997183. PubMed ID: 33747133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.